Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases. Its lead product, RUCONEST, is a recombinant human C1 esterase inhibitor approved for the treatment of acute hereditary angioedema (HAE) attacks.
Revenue (FY, 2019)
Revenue growth (FY, 2018 - FY, 2019), %
Gross profit (FY, 2019)
Gross profit margin (FY, 2019), %
Net income (FY, 2019)
EBIT (FY, 2019)
Market capitalization (22-Jul-2021)
Closing stock price (22-Jul-2021)
|Company Name||Date||Deal Size|
|Broekman Instituut B.V.|
|Pharming Americas B.V.|
|Pharming Healthcare, Inc.|
|Pharming Intellectual Property B.V.|
|Pharming Research & Development B.V.|
|Pharming Technologies B.V.|
Pharming Group revenue breakdown by geographic segment: 96.3% from U.S. and 3.7% from Other
When was Pharming Group founded?
Pharming Group was founded in 1988.
Who are Pharming Group key executives?
Pharming Group's key executives are Sijmen De Vries, Jeroen Wakkerman and Bruno M. Giannetti.
How many employees does Pharming Group have?
Pharming Group has 258 employees.
What is Pharming Group revenue?
Latest Pharming Group annual revenue is €169 m.
What is Pharming Group revenue per employee?
Latest Pharming Group revenue per employee is €655.1 k.
Who are Pharming Group competitors?
Competitors of Pharming Group include Protalix BioTherapeutics, Five Prime Therapeutics and Ambrx.
Where is Pharming Group headquarters?
Pharming Group headquarters is located at 24 Darwinweg, Leiden.
Where are Pharming Group offices?
Pharming Group has an office in Leiden.
How many offices does Pharming Group have?
Pharming Group has 2 offices.
Receive alerts for 300+ data fields across thousands of companies